Compare Amphastar Pharmaceuticals Inc (AMPH) vs Manulife Financial Corporation (MFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Manulife Financial Corporation — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Manulife Financial Corporation trades at $43.92 (market cap $73.19B). The key difference: Manulife Financial Corporation is far larger — about 84.7× Amphastar Pharmaceuticals Inc's market cap, and Manulife Financial Corporation pays a 3.08% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | MFC | |
|---|---|---|
Market Cap | $863.95M | $73.19B |
Sector | Health | Financials |
52-Week High | $30.81 | $44.77 |
52-Week Low | $16.87 | $29.90 |
Enterprise Value | $1.26B | $68.35B |
Dividend Yield | — | 3.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Manulife Financial (MFC) trades at $44.32, down 0.58% with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 results with double-digit growth in Asia and insurance sales, beating EPS expectations. Revenue reached $53.01B in 2025 with net income of $5.78B, though profit margins have moderated from 2022 peaks. Analysts maintain a Moderate Buy consensus with 57% buy ratings.
MFC presents a positive investment case with solid earnings growth, expanding Asian operations, and consistent dividend payments. However, premium valuation metrics and moderating profit margins warrant caution. The stock faces risks from wealth management outflows and competitive pressures in core markets, requiring careful monitoring of Q3 earnings performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →
